Across TCGA pan-cancer cohorts, BEAN1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BEAN1 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BEAN1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BEAN1 expression acts as an unfavorable survival marker.
UCEC are the cancer types where BEAN1 Mutation most reproducibly stratifies survival.